PMID- 16502580
OWN - NLM
STAT- MEDLINE
DCOM- 20060405
LR  - 20191026
IS  - 1543-1894 (Print)
IS  - 1543-1894 (Linking)
VI  - 125
DP  - 2006
TI  - Deletion of the derivative chromosome 9 in chronic myeloid leukemia.
PG  - 107-14
AB  - With the development of fluorescence in situ hybridization (FISH), it was 
      possible to detect the BCR-ABL fusion signal in both metaphase spreads and 
      interphase cells of patients with chronic myeloid leukemia (CML). However, the 
      use of FISH to detect residual disease in patients with CML post therapy was 
      limited by the false positive rate using the early single fusion probes. 
      Therefore, dual fusion probes that created a fusion signal on the derivative 
      chromosome 9 in addition to the fusion sifnal on the Philadelphia chromosome or 
      derivative chromosome 22 were developed. Using these second-generation probes, it 
      was discovered that a significant proportion of CML cases has a sub-microscopic 
      deletion at the site of the ABL-BCR fusion. This chapter outlines a testing 
      strategy to identify deleltions of the derivative chromosome 9 and to use 
      combinations of probes to identify residual disease in these cases.
FAU - Campbell, Lynda J
AU  - Campbell LJ
AD  - Cytogenetics Department, St Vincent's Hospital, Victoria, Australia.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Methods Mol Med
JT  - Methods in molecular medicine
JID - 101123138
RN  - EC 2.7.10.2 (Fusion Proteins, bcr-abl)
SB  - IM
MH  - Chromosome Mapping
MH  - *Chromosomes, Human, Pair 9
MH  - Fusion Proteins, bcr-abl/genetics
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*genetics
MH  - *Sequence Deletion
EDAT- 2006/03/01 09:00
MHDA- 2006/04/06 09:00
CRDT- 2006/03/01 09:00
PHST- 2006/03/01 09:00 [pubmed]
PHST- 2006/04/06 09:00 [medline]
PHST- 2006/03/01 09:00 [entrez]
AID - 10.1385/1-59745-017-0:107 [doi]
PST - ppublish
SO  - Methods Mol Med. 2006;125:107-14. doi: 10.1385/1-59745-017-0:107.